Literature DB >> 24467245

Therapeutic modulation of prostate cancer metastasis.

Sankar N Krishna1, Raymond C Bergan.   

Abstract

Targeting prostate cancer metastasis has very high therapeutic potential. Prostate cancer is the second most common cause of cancer death among men in the USA, and death results from the development of metastatic disease. In order to metastasize, cancer cells must complete a series of steps that together constitute the metastatic cascade. Each step therefore offers the opportunity for therapeutic targeting. However, practical limitations have served as limiting roadblocks to successfully targeting the metastatic cascade. They include our still-emerging understanding of the underlying biology, as well as the fact that many of the dysregulated processes have critical functionality in otherwise normal cells. We provide a discussion of the underlying biology, as it relates to therapeutic targeting. Therapeutic inroads are rapidly being made, and we present a series of case studies to highlight key points. Finally, future perspectives related to drug discovery for antimetastatic agents are discussed.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24467245     DOI: 10.4155/fmc.13.201

Source DB:  PubMed          Journal:  Future Med Chem        ISSN: 1756-8919            Impact factor:   3.808


  3 in total

1.  Genistein suppresses FLT4 and inhibits human colorectal cancer metastasis.

Authors:  Xiao Xiao; Zhiguo Liu; Rui Wang; Jiayin Wang; Song Zhang; Xiqiang Cai; Kaichun Wu; Raymond C Bergan; Li Xu; Daiming Fan
Journal:  Oncotarget       Date:  2015-02-20

2.  YTHDF1 promotes the proliferation, migration, and invasion of prostate cancer cells by regulating TRIM44.

Authors:  Weijian Li; Gaohuang Chen; Zhenyu Feng; Baoyi Zhu; Lilin Zhou; Yuying Zhang; Junyan Mai; Chonghe Jiang; Jianwen Zeng
Journal:  Genes Genomics       Date:  2021-10-22       Impact factor: 1.839

3.  Precision therapeutic targeting of human cancer cell motility.

Authors:  Li Xu; Ryan Gordon; Rebecca Farmer; Abhinandan Pattanayak; Andrew Binkowski; Xiaoke Huang; Michael Avram; Sankar Krishna; Eric Voll; Janet Pavese; Juan Chavez; James Bruce; Andrew Mazar; Antoinette Nibbs; Wayne Anderson; Lin Li; Borko Jovanovic; Sean Pruell; Matias Valsecchi; Giulio Francia; Rick Betori; Karl Scheidt; Raymond Bergan
Journal:  Nat Commun       Date:  2018-06-22       Impact factor: 14.919

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.